Show Summary Details
Page of

Chronic hepatitis and other liver disease 

Chronic hepatitis and other liver disease
Chronic hepatitis and other liver disease

Pierre Van Damme

, Tinne Lernout

, Koen Van Herck

, Rui T. Marinho

, Raymundo Paraná

, and Daniel Shouval

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2022. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 06 July 2022

Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are major risk factors in the development of hepatocellular carcinoma (HCC) either by inducing cirrhosis or by direct oncogenic effects, representing a major burden worldwide. Around 400 million people are chronically infected with HBV or HCV and approximately 1 million people die each year (~2.7% of all deaths) from causes related to viral hepatitis, most commonly cirrhosis and HCC. Alcohol consumption is responsible for increased illness and death and is associated with an increased risk of a number of cancers. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis are chronic liver diseases associated with the metabolic syndrome. This tends to take epidemic proportions in the Western population, and to constitute a major health problem in the near future. On the other hand, obesity seems to be also a strong oncogenic condition, in particular for HCC.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.